Aeovian
Biologics & Biosimilars · Health Care
Facts
as of Nov 17, 2026Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
- Employees
- 51-200estimated range
- Website
- aeovian.com
These are the key facts about Aeovian on Alion as of Nov 17, 2026. The latest round is Venture - Series Unknown of $37M, announced in 2019.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Financials
Funding rounds, investors and revenue on record.
$37MTotal raised
Venture - Series UnknownLatest round
1Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
$37M
Sources: funding announcements, grant and company registers
Milestones
Oct 12, 2019
Raised a round Venture round $37M · Chemical & Engineering News
Each milestone is dated by its source: registers, filings, the press
Newsroom
Dec 27, 20252025
News · Pulse 2.0
Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company based in Berkeley, California, has closed an oversubscribed $55 million Series B financing to support completi…
Dec 16, 20252025
News · YahooFinance
The TSC Alliance Endowment Fund, a supporting organization of the TSC Alliance, has invested in Aeovian Pharmaceuticals as part of their Series B financing in support of their Ph…
Apr 3, 20242024
News · Pulse 2.0
Aeovian Pharmaceuticals - a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway - announced that…
Mar 28, 20242024
Press release · PRNewswire
/PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit...
Dec 26, 20232023
News · bioworld.com
Aeovian Pharmaceuticals Inc. has disclosed new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegenerative di…
Oct 12, 20192019
News · Chemical & Engineering News
Chemical & Engineering News (C&EN): Keeping you up to date with the chemistry news that matters most. Published by the American Chemical Society.
Sources: the outlets named on each headline, each story once
